UAB Researchers Discover why Brain Neurons in Parkinson's Disease Stop Benefiting from Levodopa
The mechanism may be therapeutic target to prevent or reverse dyskinesia
Though the drug levodopa (L-DOPA) can dramatically improve Parkinson’s disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition – involuntary repetitive, rapid and jerky movements. This abnormal motor behavior appears only while taking L-DOPA, a it stops if the drug is stopped. However, if L-DOPA is taken again, even many months later, it quickly re-emerges. In research to prevent this side effect and extend the usefulness of L-DOPA – which is the most effective drug treatment for Parkinson’s disease – University of Alabama at Birmingham researchers have uncovered an essential mechanism of this long-term memory for L-DOPA-induced-dyskinesia, or LID. To read more, click here.
Spine World Summit
Jan. 26, 2018 - Jan. 27, 2018; Hong Kong
6th Ottawa Neurosurgery Review Course
Feb. 3, 2018 - Feb. 10, 2018; Ottawa, ON Canada
Winter Clinics for Cranial and Spinal Surgery
Feb. 25, 2018 - Mar. 1, 2018; Snowmass Village, Colo.
69th Southern Neurosurgical Society Annual Meeting
Feb. 28, 2018 - Mar. 3, 2018; San Juan, PR
Second International Brain Mapping Course
April 26-27, 2018; New Orleans